<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914472</url>
  </required_header>
  <id_info>
    <org_study_id>HEPHIP0509</org_study_id>
    <secondary_id>Version 01</secondary_id>
    <nct_id>NCT00914472</nct_id>
  </id_info>
  <brief_title>Comparison of Two Heparin Formulations in Patients With Chronic Renal Failure.</brief_title>
  <acronym>HEPHIP0509</acronym>
  <official_title>A Randomized Non-inferiority Clinical Trial of Heparin Produced by Hipolabor Laboratory(PARINEXÂ®) in Comparation With Heparin Produced by APP PHARMACEUTICALS in Patients With Chronic Renal Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azidus Brasil</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azidus Brasil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate, through a randomized, open, parallel and comparative, non-inferiority of heparin
      sodium produced by laboratory Hipolabor compared to heparin manufactured by APP in patients
      on hemodialysis due to renal failure, through the control of hemostasis, verified by
      formation of clot (fibrin) in the hemodialysis system and pharmacodynamic parameters (TTPA
      and Anti-Xa) during the use of heparin
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of heparin in thrombi formation.</measure>
    <time_frame>12 consecutive sessions</time_frame>
    <description>During 4 weeks (3 times/week)of treatment will be avaluete thrombi formation in the dialysis system and decrease in net volume of the capillary dialyzer (primming) under formation of fibrin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration of the pharmacodynamic parameters.</measure>
    <time_frame>12 consecutive sessions.</time_frame>
    <description>During 4 weeks (3 times/week)of treatment will be avaluate evoluation fo TTPA and ANTI-XA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Anti-Xa</measure>
    <time_frame>12 consecutive sessions (4 weeks - 3times/week)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thrombus</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heparin - Hipolabor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ative comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin - APP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>heparin sodium - APP</intervention_name>
    <description>Heparin 5000 IU / mL</description>
    <arm_group_label>Ative comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Heparin sodium - Hipolabor</intervention_name>
    <description>Heparin 5000 IU / mL</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Research that patients agreed to participate and signed the written informed consent;

          2. Patients aged over 18 years, both sexes, regardless of color or social class;

          3. Patients with impaired renal function in chronic hemodialysis schedule of at least 3
             times a week and giving the use of heparin in the prophylaxis of thrombosis in the
             system.

        Exclusion Criteria:

          1. Hypersensitivity to heparin sodium and / or benzyl alcohol;

          2. History of bleeding or disease that the change of blood coagulation could aggravate or
             terminate the clinical manifestations, such as tables of active peptic or gastric
             ulcer;

          3. Severe liver disease;

          4. Cancer;

          5. Period of gestation;

          6. Genetic abnormality of the coagulation system;

          7. Multiple trauma;

          8. Use of aspirin in high doses (above 200mg per day);

          9. Use of glucocorticoids for at least 1 month;

         10. Use of other anticoagulants;

         11. Submission of a big surgery done less than 15 days;

         12. History of persistent hypertension at the end of dialysis than 150/100 mmHg;

         13. Indicated doses of heparin 20% above or below 150UI/kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lal Clinica Pesquisa E Desenvolvimento Ltda</name>
      <address>
        <city>Valinhos</city>
        <state>SP</state>
        <zip>13270000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>October 26, 2010</last_update_submitted>
  <last_update_submitted_qc>October 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Frederico</name_title>
    <organization>LAL Clinica Pesquisa e Desenvolvimento Ltda</organization>
  </responsible_party>
  <keyword>Preventing the thrombi formation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

